Literature DB >> 9803048

Dyspnea in the advanced cancer patient.

D J Dudgeon1, M Lertzman.   

Abstract

Optimal management of dyspnea in terminal cancer patients requires an understanding of the responsible pathophysiological mechanisms. This prospective study assessed visual analogue scales (VAS) of shortness of breath (SOB) and anxiety, bedside spirometry, maximum inspiratory pressure (MIP), chest radiography, arterial blood gases, hemoglobin, and electrocardiogram, if indicated, in 100 terminally ill cancer patients. Forty-nine percent of the patients had lung cancer. The median VAS scores for SOB and anxiety were 53 mm and 29 mm, respectively. Spirometry was abnormal in 93% of patients, with 5% having obstructive, 41% restrictive, and 47% mixed patterns. The median MIP was 16 cm H2O. Sixty-five percent of the patients had parenchymal or pleural involvement on chest radiograph. Twenty-nine percent had evidence of cardiac ischemia, recent or current myocardial infarction or atrial fibrillation. Patients had a median of five different abnormalities that could have contributed to their shortness of breath. Only anxiety (p = 0.001), a history of smoking (p = 0.02), and pCO2 levels were statistically significantly correlated with SOB VAS scores. The potentially correctable causes of dyspnea included hypoxia (40%), anemia (20%), and bronchospasm (52%). The finding of very low MIPs suggests severe respiratory muscle weakness may contribute significantly to dyspnea in this patient population. Further studies are needed to confirm this finding and characterize the underlying pathophysiology.

Entities:  

Mesh:

Year:  1998        PMID: 9803048     DOI: 10.1016/s0885-3924(98)00065-7

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  20 in total

1.  Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference.

Authors:  David Currow; Miriam Johnson; Patrick White; Amy Abernethy
Journal:  Br J Gen Pract       Date:  2013-11       Impact factor: 5.386

2.  Dyspnea in palliative care: expanding the role of corticosteroids.

Authors:  Richard J Lin; Ronald D Adelman; Sonal S Mehta
Journal:  J Palliat Med       Date:  2012-03-02       Impact factor: 2.947

Review 3.  Palliative care in lung cancer.

Authors:  Betty Ferrell; Marianna Koczywas; Fred Grannis; Annie Harrington
Journal:  Surg Clin North Am       Date:  2011-04       Impact factor: 2.741

4.  Pain Management and Symptom-Oriented Drug Therapy in Palliative Care.

Authors:  Carsten Klein; Ute Lang; Johannes Bükki; Reinhard Sittl; Christoph Ostgathe
Journal:  Breast Care (Basel)       Date:  2011-02-22       Impact factor: 2.860

5.  The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer.

Authors:  Digant Gupta; Christopher G Lis; James F Grutsch
Journal:  Support Care Cancer       Date:  2006-11-21       Impact factor: 3.603

6.  Oral morphine and respiratory function amongst hospice inpatients with advanced cancer.

Authors:  T D Walsh; N I Rivera; R Kaiko
Journal:  Support Care Cancer       Date:  2003-10-24       Impact factor: 3.603

7.  Measurement of diaphragmatic length during the breathing cycle by dynamic MRI: comparison between healthy adults and patients with an intrathoracic tumor.

Authors:  Christian Plathow; Christian Fink; Sebastian Ley; Michael Puderbach; Monica Eichinger; Astrid Schmähl; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2004-05-01       Impact factor: 5.315

Review 8.  An approach to dyspnea in advanced disease.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2003-12       Impact factor: 3.275

Review 9.  The symptomatic relief of dyspnea.

Authors:  Giovanni Elia; Jay Thomas
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

10.  Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels.

Authors:  Marcella Daniel; Francis J Keefe; Pauline Lyna; Bercedis Peterson; Jennifer Garst; Mike Kelley; Gerold Bepler; Lori A Bastian
Journal:  J Pain       Date:  2009-03       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.